Immune targeting of cancer stem cells in gastrointestinal oncology

Robert J Canter, Steven K. Grossenbacher, Erik Ames, William J Murphy

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The cancer stem cell (CSC) hypothesis postulates that a sub-population of quiescent cells exist within tumors which are resistant to conventional cytotoxic/anti-proliferative therapies. It is these CSCs which then seed tumor relapse, even in cases of apparent complete response to systemic therapy. Therefore, therapies, such as immunotherapy, which add a specific anti-CSC strategy to standard cytoreductive treatments may provide a promising new direction for future cancer therapies. CSCs are an attractive target for immune therapies since, unlike chemotherapy or radiotherapy, immune effector cells do not specifically require target cells to be proliferating in order to effectively kill them. Although recent advances have been made in the development of novel systemic and targeted therapies for advanced gastro-intestinal (GI) malignancies, there remains an unmet need for durable new therapies for these refractory malignancies. Novel immunotherapeutic strategies targeting CSCs are in pre-clinical and clinical development across the spectrum of the immune system, including strategies utilizing adaptive immune cell-based effectors, innate immune effectors, as well as vaccine approaches. Lastly, since important CSC functions are affected by the tumor microenvironment, targeting of both cellular (myeloid derived suppressor cells and tumorassociated macrophages) and sub-cellular (cytokines, chemokines, and PD1/PDL1) components of the tumor microenvironment is under investigation in the immune targeting of CSCs. These efforts are adding to the significant optimism about the potential utility of immunotherapy to overcome cancer resistance mechanisms and cure greater numbers of patients with advanced malignancy.

Original languageEnglish (US)
Pages (from-to)S1-S10
JournalJournal of Gastrointestinal Oncology
Volume7
DOIs
StatePublished - Apr 1 2016

Fingerprint

Neoplastic Stem Cells
Neoplasms
Tumor Microenvironment
Therapeutics
Immunotherapy
Chemokines
Immune System
Seeds
Radiotherapy
Vaccines
Macrophages
Cytokines
Recurrence
Drug Therapy

Keywords

  • Aldehyde dehydrogenase (ALDH)
  • Cancer stem cells (CSCs)
  • CD133
  • CD24
  • CD44
  • EpCAM
  • Immunotherapy
  • Natural killer (NK) cells
  • T cells
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Immune targeting of cancer stem cells in gastrointestinal oncology. / Canter, Robert J; Grossenbacher, Steven K.; Ames, Erik; Murphy, William J.

In: Journal of Gastrointestinal Oncology, Vol. 7, 01.04.2016, p. S1-S10.

Research output: Contribution to journalReview article

@article{8f56d2e83ab64ccd8ad5d24cd6575e29,
title = "Immune targeting of cancer stem cells in gastrointestinal oncology",
abstract = "The cancer stem cell (CSC) hypothesis postulates that a sub-population of quiescent cells exist within tumors which are resistant to conventional cytotoxic/anti-proliferative therapies. It is these CSCs which then seed tumor relapse, even in cases of apparent complete response to systemic therapy. Therefore, therapies, such as immunotherapy, which add a specific anti-CSC strategy to standard cytoreductive treatments may provide a promising new direction for future cancer therapies. CSCs are an attractive target for immune therapies since, unlike chemotherapy or radiotherapy, immune effector cells do not specifically require target cells to be proliferating in order to effectively kill them. Although recent advances have been made in the development of novel systemic and targeted therapies for advanced gastro-intestinal (GI) malignancies, there remains an unmet need for durable new therapies for these refractory malignancies. Novel immunotherapeutic strategies targeting CSCs are in pre-clinical and clinical development across the spectrum of the immune system, including strategies utilizing adaptive immune cell-based effectors, innate immune effectors, as well as vaccine approaches. Lastly, since important CSC functions are affected by the tumor microenvironment, targeting of both cellular (myeloid derived suppressor cells and tumorassociated macrophages) and sub-cellular (cytokines, chemokines, and PD1/PDL1) components of the tumor microenvironment is under investigation in the immune targeting of CSCs. These efforts are adding to the significant optimism about the potential utility of immunotherapy to overcome cancer resistance mechanisms and cure greater numbers of patients with advanced malignancy.",
keywords = "Aldehyde dehydrogenase (ALDH), Cancer stem cells (CSCs), CD133, CD24, CD44, EpCAM, Immunotherapy, Natural killer (NK) cells, T cells, Vaccines",
author = "Canter, {Robert J} and Grossenbacher, {Steven K.} and Erik Ames and Murphy, {William J}",
year = "2016",
month = "4",
day = "1",
doi = "10.3978/j.issn.2078-6891.2015.066",
language = "English (US)",
volume = "7",
pages = "S1--S10",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",

}

TY - JOUR

T1 - Immune targeting of cancer stem cells in gastrointestinal oncology

AU - Canter, Robert J

AU - Grossenbacher, Steven K.

AU - Ames, Erik

AU - Murphy, William J

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The cancer stem cell (CSC) hypothesis postulates that a sub-population of quiescent cells exist within tumors which are resistant to conventional cytotoxic/anti-proliferative therapies. It is these CSCs which then seed tumor relapse, even in cases of apparent complete response to systemic therapy. Therefore, therapies, such as immunotherapy, which add a specific anti-CSC strategy to standard cytoreductive treatments may provide a promising new direction for future cancer therapies. CSCs are an attractive target for immune therapies since, unlike chemotherapy or radiotherapy, immune effector cells do not specifically require target cells to be proliferating in order to effectively kill them. Although recent advances have been made in the development of novel systemic and targeted therapies for advanced gastro-intestinal (GI) malignancies, there remains an unmet need for durable new therapies for these refractory malignancies. Novel immunotherapeutic strategies targeting CSCs are in pre-clinical and clinical development across the spectrum of the immune system, including strategies utilizing adaptive immune cell-based effectors, innate immune effectors, as well as vaccine approaches. Lastly, since important CSC functions are affected by the tumor microenvironment, targeting of both cellular (myeloid derived suppressor cells and tumorassociated macrophages) and sub-cellular (cytokines, chemokines, and PD1/PDL1) components of the tumor microenvironment is under investigation in the immune targeting of CSCs. These efforts are adding to the significant optimism about the potential utility of immunotherapy to overcome cancer resistance mechanisms and cure greater numbers of patients with advanced malignancy.

AB - The cancer stem cell (CSC) hypothesis postulates that a sub-population of quiescent cells exist within tumors which are resistant to conventional cytotoxic/anti-proliferative therapies. It is these CSCs which then seed tumor relapse, even in cases of apparent complete response to systemic therapy. Therefore, therapies, such as immunotherapy, which add a specific anti-CSC strategy to standard cytoreductive treatments may provide a promising new direction for future cancer therapies. CSCs are an attractive target for immune therapies since, unlike chemotherapy or radiotherapy, immune effector cells do not specifically require target cells to be proliferating in order to effectively kill them. Although recent advances have been made in the development of novel systemic and targeted therapies for advanced gastro-intestinal (GI) malignancies, there remains an unmet need for durable new therapies for these refractory malignancies. Novel immunotherapeutic strategies targeting CSCs are in pre-clinical and clinical development across the spectrum of the immune system, including strategies utilizing adaptive immune cell-based effectors, innate immune effectors, as well as vaccine approaches. Lastly, since important CSC functions are affected by the tumor microenvironment, targeting of both cellular (myeloid derived suppressor cells and tumorassociated macrophages) and sub-cellular (cytokines, chemokines, and PD1/PDL1) components of the tumor microenvironment is under investigation in the immune targeting of CSCs. These efforts are adding to the significant optimism about the potential utility of immunotherapy to overcome cancer resistance mechanisms and cure greater numbers of patients with advanced malignancy.

KW - Aldehyde dehydrogenase (ALDH)

KW - Cancer stem cells (CSCs)

KW - CD133

KW - CD24

KW - CD44

KW - EpCAM

KW - Immunotherapy

KW - Natural killer (NK) cells

KW - T cells

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84995773059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995773059&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2015.066

DO - 10.3978/j.issn.2078-6891.2015.066

M3 - Review article

AN - SCOPUS:84995773059

VL - 7

SP - S1-S10

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

ER -